Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sara Mekuria

Cardiovascular Disease Frederick, MD Medical Doctor

NPI 1861650111 CMS profile 758406

180 Thomas Johnson Drive, Suite 202, Frederick, MD 21702

Open in the dashboard

General payments

$3,617

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Mekuria of Frederick, MD is reported in the CMS Open Payments database as having received $3,617 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $934 44
2024 General $634 35
2023 General $958 46
2022 General $754 42
2021 General $233 16
2020 General $37 3
2019 General $65 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Mekuria
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Sara Mekuria were reported at $934. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Sara Mekuria Cardiovascular Disease median Middle half National median
2019 $65 $450 $127–$1,392 $163
2020 $37 $242 $77–$751 $114
2021 $233 $335 $101–$1,037 $132
2022 $754 $395 $121–$1,211 $149
2023 $958 $443 $136–$1,283 $160
2024 $634 $450 $136–$1,323 $164
2025 $934 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $398 24 payments
  2. Novo Nordisk Inc $383 22 payments
  3. Novartis Pharmaceuticals Corporation $294 14 payments
  4. Amgen Inc. $273 13 payments
  5. Pfizer Inc. $202 11 payments
  6. AstraZeneca Pharmaceuticals LP $197 9 payments
  7. Philips Electronics North America Corporation $181 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $164 8 payments
  9. E.R. Squibb & Sons, L.L.C. $157 8 payments
  10. Kowa Pharmaceuticals America, Inc. $145 11 payments
  11. Other $1,223 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,560 187 payments
  2. Education $57 2 payments
Products named General payments · program years 2019–2025
  1. VERQUVO Cardiovascular $398 24 payments
  2. Wegovy $243 15 payments
  3. LEQVIO $195 9 payments
  4. (5044) MCOT $181 11 payments
  5. ELIQUIS $177 10 payments
  6. VERQUVO Cardiovascular $174 10 payments
  7. REPATHA $148 6 payments
  8. Livalo $145 11 payments
  9. Ozempic $140 7 payments
  10. BRILINTA $138 7 payments
  11. Other $2,132 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,810

Median for Cardiology: 2,533

Drug cost

$585,783

Median for Cardiology: $485,213

Branded share of claims

22.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 209 $297,223
Entresto Sacubitril/Valsartan Brand 69 $123,341
Xarelto Rivaroxaban Brand 33 $44,478
Brilinta Ticagrelor Brand 15 $17,023
Nexlizet Bempedoic Acid/Ezetimibe Brand 17 $16,316
Jardiance Empagliflozin Brand 14 $16,243
Praluent Pen Alirocumab Brand 16 $12,866
Droxidopa Generic 16 $9,933
Metoprolol Succinate Generic 325 $5,318
Rosuvastatin Calcium Generic 167 $4,353

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$297,893

Medicare's payments for the services billed

Medicare patients

810

Average age 74

Services billed

3,589

491 women, 319 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 36%
Diabetes 33%
Depression 26%
Atrial fibrillation 24%
Chronic kidney disease 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $121
$121 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $115
$115 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $74
$74 — —
INJECTAFER
  • Daiichi Sankyo Inc. $56
$56 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record